Securities code: 688399 securities abbreviation: Jiangsu Bioperfectus Technologies Co.Ltd(688399) Announcement No.: 2022-002 Jiangsu Bioperfectus Technologies Co.Ltd(688399) announcement of annual performance increase in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
(1) According to the preliminary calculation of the financial department, the net profit attributable to the owners of the parent company in 2021 is expected to be 113 million yuan to 135 million yuan, an increase of 310.43 million yuan to 53.43 million yuan, a year-on-year increase of 37.88% to 64.72% compared with the same period of the previous year (legally disclosed data).
(2) The net profit attributable to the owners of the parent company after deducting non recurring profits and losses is 110 million yuan to 132 million yuan, which will increase by 318.54 million yuan to 538.54 million yuan, an increase of 40.76% to 68.91% year-on-year compared with the same period of the previous year (statutory disclosure data).
1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
(1) According to the preliminary calculation of the financial department, it is expected that the net profit attributable to the owners of the parent company in 2021 will increase by 310.43 million yuan to 53.43 million yuan, a year-on-year increase of 37.88% to 64.72% compared with the same period of the previous year (legally disclosed data).
(2) Compared with the same period of last year (legally disclosed data), the net profit attributable to the owner of the parent company after deducting non recurring profits and losses will increase by 318.54 million yuan to 538.54 million yuan, a year-on-year increase of 40.76% to 68.91%.
(3) This performance forecast has not been audited.
2、 Performance in the same period of last year
In 2020, the net profit attributable to the owner of the parent company was 819.57 million yuan. Net profit attributable to the owner of the parent company after deducting non recurring profits and losses: 78.146 million yuan. 3、 Main reasons for performance changes in the current period
(I) main business impact
During the reporting period, although the epidemic situation in China has been effectively controlled, there are still sporadic cases and repeated cases in some areas. There is still a strong demand for covid-19 nucleic acid detection reagents. The company continues to be committed to the cause of epidemic prevention and control. In view of the normalization of the epidemic situation, the company has accumulated efficient ability to respond to the new normal of covid-19 epidemic situation, and the sales of covid-19 nucleic acid detection reagents have increased significantly, It also led to a substantial increase in the sales of other covid-19 related products; In addition, under the condition that the epidemic situation has been effectively controlled, the company has strengthened the R & D, production and sales of original products such as nucleic acid extraction reagent, HPV and BV, and the sales range has also increased significantly. The above reasons promote the company’s overall operating performance to show a large-scale growth in 2021.
(II) other impacts: there are no non recurring profits and losses, accounting treatment and other major factors.
4、 Risk tips:
The company has not found any major uncertain factors affecting the accuracy of the performance forecast, and the forecast has not been audited.
Whether the company’s future sales performance can continue to maintain a significant growth trend is uncertain, which is affected by many factors, such as epidemic development and epidemic prevention and control policies, market competition, the company’s product competitiveness and channel ability, customer recognition and the company’s overseas business promotion, The sales and profit contribution of covid-19 products are uncertain. Please pay attention to the investment risk.
5、 Other explanatory matters
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Board of directors of Jiangsu shuoshi Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd. January 17, 2022
